|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 AUD | +4.35% |
|
+14.29% | +4.35% |
| Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
| Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Arovella Therapeutics Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was AUD 0.405898 million compared to AUD 0.29581 million a year ago. Net loss was AUD 10.18 million compared to AUD 8.62 million a year ago.
Basic loss per share from continuing operations was AUD 0.0143 compared to AUD 0.0157 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +4.35% | 82.18M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
AROVELLA THERAPEUTICS LIMITED 
